Roche takes worldwide rights to a Zymeworks trispecific T-cell engager
- Roche will pay Zymeworks $55 million upfront for worldwide rights to a preclinical trispecific T cell engager.
- Total potential value is up to $813 million.
- Endpoints notes the molecule could go head-to-head with Amgen's Imdelltra.
💡 Points
A $55M upfront on an $813M headline for a preclinical asset is a standard option-style structure: Roche pays little until the molecule proves itself. The interesting angle is the benchmark, since pointing at Imdelltra implies a DLL3-type small cell lung cancer ambition. For Zymeworks it validates the multispecific platform without the cost of clinical development.
Roche taps Zymeworks in up to $813M deal for preclinical T cell engager ↗